Evidence map›Paper›PMID 27179035›Full record

ArticleIntegrative cancer therapies2016

Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro.

Lei Bi, Xiaojing Yan, Weiping Chen, Jing Gao, Lei Qian, Shuang Qiu

Open access · goldAbstract read
In one paragraph

Article in Integrative cancer therapies, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lei BiDepartment of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Xiaojing YanChangzhou Affiliated Hospital, Nanjing University of Chinese Medicine, Changzhou, China.
Weiping ChenDepartment of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China wp2002123@163.com.
Jing GaoDepartment of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Lei QianDepartment of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Shuang QiuDepartment of Preclinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetramethylpyrazine (TMP) was originally isolated from a traditional Chinese herbal medicine, Ligusticum chuanxiong In the present study, TMP exhibits potent antitumor activities in vitro. However, the molecular mechanisms remain to be defined. Hence, this study aims to investigate the antiproliferative and apoptotic effects of TMP on HepG2 and elucidate the underlying mechanisms. Analyses using Cell Counting Kit-8 and real-time cell analyzer indicated that TMP significantly inhibited HepG2 cell proliferation. We also observed that TMP induced cell cycle arrest at the G0/G1 checkpoint and apoptosis, using flow cytometry and high-content screening. Furthermore, our results predicted that TMP could directly decrease mitochondrial membrane potential (Δψm), increase the release of cytochrome c, and increase caspase activation, indicating that mitochondrial pathway apoptosis could be the mechanism for TMP within HepG2 cells. Moreover, TMP altered expression of p53 and the Bcl-2/Bax protein ratio, which revealed that TMP induced cell cycle arrest and caspase-dependent mitochondrial apoptosis in HepG2 cells in vitro. These studies provided mechanistic insights into the antitumor properties of TMP, which may be explored as a potential option for treatment of hepatocellular carcinoma.

Indexed as

Apoptosisbcl-2-Associated X ProteinCarcinoma, HepatocellularCell Cycle CheckpointsCell Line, TumorCell ProliferationCytochromes cG1 Phase Cell Cycle CheckpointsHep G2 CellsHumansLiver NeoplasmsMembrane Potential, MitochondrialMitochondriaProto-Oncogene Proteins c-bcl-2PyrazinesResting Phase, Cell Cyclebcl-2-Associated X ProteinCytochromes cProto-Oncogene Proteins c-bcl-2PyrazinestetramethylpyrazineTP53 protein, humanTumor Suppressor Protein p53caspase activationcytochrome c releasehepatocellular carcinomamitochondrial pathway apoptosisp53tetramethylpyrazine (TMP)

Identifiers

PMID27179035
PMCPMC5736061
OpenAlexW2380012520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.